We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals

110 hedge funds and large institutions have $622M invested in Vanda Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 38 increasing their positions, 37 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

434% more call options, than puts

Call options by funds: $40.9M | Put options by funds: $7.66M

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

9% more capital invested

Capital invested by funds: $571M → $622M (+$51.2M)

4% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 23

3% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 37

1% more funds holding

Funds holding: 109110 (+1)

Holders
110
Holders Change
+1
Holders Change %
+0.92%
% of All Funds
3.16%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
24
Increased
38
Reduced
37
Closed
23
Calls
$40.9M
Puts
$7.66M
Net Calls
+$33.2M
Net Calls Change
-$10.4M
Name Holding Trade Value Shares
Change
Change in
Stake
LPL Financial
126
LPL Financial
California
-$247K -15,200 Closed
SG Americas Securities
127
SG Americas Securities
New York
-$232K -14,293 Closed
SCM
128
Sterling Capital Management
North Carolina
-$172K -10,589 Closed
TC
129
TradeLink Capital
Illinois
-$146K -9,000 Closed
PAM
130
Panagora Asset Management
Massachusetts
-$47K -2,864 Closed
Canada Pension Plan Investment Board
131
Canada Pension Plan Investment Board
Ontario, Canada
-$34K -2,100 Closed
QT
132
Quantbot Technologies
New York
-$30K -1,900 Closed
GC
133
Globeflex Capital
California
-$1K -71 Closed

VNDA Hedge Fund Activity: Q2 2014 in Review

110 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2014, worth a combined $622M — up 9% from $571M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new VNDA positions and 23 closed out — a net gain of 1 holder — while 38 added to existing stakes and 37 trimmed.

The largest buyer was Paulson & Co, adding an estimated $24.1M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $19.9M sold.

  • 110 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2014, up from 109 in Q1 2014.
  • Funds reported $622M of Vanda Pharmaceuticals stock for Q2 2014, up 9% quarter-over-quarter.
  • 24 funds opened new Vanda Pharmaceuticals positions in Q2 2014 and 23 closed out, a net change of +1 holder.
  • The largest Vanda Pharmaceuticals buyer in Q2 2014 was Paulson & Co, an estimated $24.1M added.
  • The largest Vanda Pharmaceuticals seller in Q2 2014 was Consonance Capital Management, an estimated $19.9M sold.

Based on aggregated 13F filings for Q2 2014.